<code id='F7D2A20F24'></code><style id='F7D2A20F24'></style>
    • <acronym id='F7D2A20F24'></acronym>
      <center id='F7D2A20F24'><center id='F7D2A20F24'><tfoot id='F7D2A20F24'></tfoot></center><abbr id='F7D2A20F24'><dir id='F7D2A20F24'><tfoot id='F7D2A20F24'></tfoot><noframes id='F7D2A20F24'>

    • <optgroup id='F7D2A20F24'><strike id='F7D2A20F24'><sup id='F7D2A20F24'></sup></strike><code id='F7D2A20F24'></code></optgroup>
        1. <b id='F7D2A20F24'><label id='F7D2A20F24'><select id='F7D2A20F24'><dt id='F7D2A20F24'><span id='F7D2A20F24'></span></dt></select></label></b><u id='F7D2A20F24'></u>
          <i id='F7D2A20F24'><strike id='F7D2A20F24'><tt id='F7D2A20F24'><pre id='F7D2A20F24'></pre></tt></strike></i>

          explore

          explore

          author:hotspot    Page View:67682
          Nasdaq
          Mark Lennihan/AP

          The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

          Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

          advertisement

          Acelyrin’s share price fell more than 60% in after-hours trading Monday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more
          Readout Newsletter: Biogen, Ionis, Johnson & Johnson news
          Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

          AdobeTheneed-to-knowthismorningBiogen and IonisPharmaceuticals are endingtheirdevelopment ofanexperi

          read more
          Virginia high school admissions case could be legal follow
          Virginia high school admissions case could be legal follow

          3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

          read more

          HCA says smaller share of spending going to labor

          AdobeThechiefexecutiveofthecountry’sbiggesthospitalchainsaidThursdaythatlaborcostsarenowlowerasaperc